Comparative Pharmacology
Head-to-head clinical analysis: MERILOG versus NOVOLIN 70 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MERILOG versus NOVOLIN 70 30.
MERILOG vs NOVOLIN 70/30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Merilog is a recombinant human insulin analog that lowers blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. It also inhibits lipolysis and proteolysis, and enhances protein synthesis.
Novolin 70/30 is a biphasic insulin analog consisting of 70% insulin aspart protamine suspension (intermediate-acting) and 30% insulin aspart (rapid-acting). It lowers blood glucose by promoting peripheral glucose uptake, inhibiting hepatic gluconeogenesis, and suppressing lipolysis and proteolysis.
10 mg orally once daily, with or without food.
Subcutaneous injection, 0.5-1 unit/kg/day divided into 2-3 doses, typically before meals and at bedtime; adjust based on blood glucose monitoring.
None Documented
None Documented
The terminal elimination half-life is approximately 18 hours, allowing for once-daily dosing in most patients. In renal impairment (CrCl <30 mL/min), half-life is prolonged to >40 hours, requiring dose adjustment.
Terminal half-life for NPH component is approximately 13 hours; regular insulin component half-life is 5-6 hours. Clinical context: Provides basal coverage for 18-24 hours.
MERILOG is primarily excreted renally as unchanged drug (85%) and as minor metabolites (10%). Fecal excretion accounts for less than 5%.
Renal: 30-80% of administered insulin is excreted via kidneys; remainder is metabolized in liver and muscle. Biliary/fecal excretion is negligible.
Category C
Category C
Insulin
Insulin